Updated from 9:45 a.m. EST
announced Monday that the European Commission has approved marketing of prasugrel, an anti-clotting drug it developed with
Prasugrel, or Efient, which European officials approved to help prevent blood clots in heart patients with stents, will compete with Plavix, sold by
Food and Drug Administration
use of prasugrel in patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI). Analysts say if approved in the U.S., the drug could bring in $1 billion in annual revenue.
Lilly shares were down 0.8% to $32.98 in recent trading.